PharmaCyte increases TNF Pharmaceuticals stake by $3 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 2, 2025 9:20 AM EDTTNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartners 2025 Hype Cycle for Data Center Infrastructure Technologies
LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, TNF) by an additional $3 million. The Company does so to help support TNFs recent acquisition of a license with LightSolver, Ltd. (LightSolver), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing... More
